Portal de Periódicos da CAPES

A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth

2013; Nature Portfolio; Volume: 4; Issue: 1 Linguagem: Inglês

10.1038/ncomms3035

2041-1723

Lei Wang, Jianjun Chang, Diana Varghese, Michael T. Dellinger, Subodh Kumar, Anne M. Best, Julio C. Ruiz, Richard Bruick, Samuel Peña‐Llopis, Junjie Xu, David J. Babinski, Doug E. Frantz, Rolf A. Brekken, Amy Quinn, Anton Simeonov, Johnny Easmon, Elisabeth D. Martínez,

Ubiquitin and proteasome pathways

The pharmacological inhibition of general transcriptional regulators has the potential to block growth through targeting multiple tumorigenic signalling pathways simultaneously. Here, using an innovative cell-based screen, we identify a structurally unique small molecule (named JIB-04) that specifically inhibits the activity of the Jumonji family of histone demethylases in vitro, in cancer cells, and in tumours in vivo. Unlike known inhibitors, JIB-04 is not a competitive inhibitor of α-ketoglutarate. In cancer, but not in patient-matched normal cells, JIB-04 alters a subset of transcriptional pathways and blocks viability. In mice, JIB-04 reduces tumour burden and prolongs survival. Importantly, we find that patients with breast tumours that overexpress Jumonji demethylases have significantly lower survival. Thus, JIB-04, a novel inhibitor of Jumonji demethylases in vitro and in vivo, constitutes a unique potential therapeutic and research tool against cancer, and validates the use of unbiased cellular screens to discover chemical modulators with disease relevance. Epigenetic regulators are promising targets for cancer drugs, as they can modulate a broad range of transcriptional networks simultaneously. Here, the authors identify an inhibitor of Jumonji-family histone demethylases and show that it selectively kills cancer cells in mouse tumour models.